[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338232-105":59,"doc-detail-338232-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp-enzymes-and-mono-adp-ribosylation-advancing-the-connection-from-interferonsignalling-to-cancer-biology","PARP enzymes and mono-ADP-ribosylation - advancing the connection from interferonsignalling to cancer biology","","ADP-ribosyltransferases of the PARP family include enzymes with diverse regulatory roles across cellular life, from DNA damage repair to control of cell-cycle progression and immune response. PARP1/2 inhibitors have become major therapies for ovarian, pancreatic, prostate, and breast cancers, particularly with DNA-repair gene mutations. Recent progress in mono-ADP-ribosylation has enabled development of selective PARP inhibitors targeting mono-ADP-ribosylation activity, while this review highlights interferon-stimulated PARPs in cancer progression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-enzymes-and-mono-adp-ribosylation-advancing-the-connection-from-interferonsignalling-to-cancer-biology/338232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-enzymes-and-mono-adp-ribosylation-advancing-the-connection-from-interferonsignalling-to-cancer-biology/338232.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is mono-ADP-ribosylation and how is it related to PARP enzymes?","Question",{"text":112,"@type":113},"Mono-ADP-ribosylation refers to transfer of single ADP-ribose units to targets. PARP family enzymes mainly drive intracellular ADP-ribosylation, with PARPs categorized into mono-ARTs and poly-ARTs based on catalytic activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are PARP1/2 inhibitors important in cancer therapy?",{"text":117,"@type":113},"PARP1/2 inhibitors are used as mainstay pharmaceutical strategies for ovarian, pancreatic, prostate, and breast cancers. Their effectiveness is linked to mutations in genes involved in DNA repair mechanisms, described as synthetic lethality.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PARP7 influence interferon type I signaling in cancer cells?",{"text":121,"@type":113},"PARP7 acts as a repressor of the interferon type I (IFN-I) pathway by MARylating and deactivating pathway components, such as TBK1. This negative regulation helps cancer cells escape immune surveillance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338232,1790876847,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Expert Reviews in Molecular Medicine  \n[cambridge.org/erm](cambridge.org/erm)  \nReview  \nCite this article: Morone B, Grimaldi G (2024) . PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferonsignalling to cancer biology. Expert Reviews in Molecular Medicine 26, e17, 1–8. [https://](https://)[ ](https://)[doi.org/10.1017/erm.2024.13](doi.org/10.1017/erm.2024.13)  \nReceived: 30 November 2023  \nRevised: 5 March 2024  \nAccepted: 20 March 2024  \nKeywords:  \ncancer-targeted therapy; interferon-signalling; mono-ADP-ribosylation; PARP inhibitors; PARPs  \nCorresponding author:  \nGiovanna Grimaldi;  \nEmail: [g.grimaldi@ieos.cnr.it](g.grimaldi@ieos.cnr.it)  \n© The Author(s), 2024 . Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.  \nPARP enzymes and mono-ADP-ribosylation: advancing the connection from interferonsignalling to cancer biology  \nBarbara Morone and Giovanna Grimaldi  \nInstitute for Endocrinology and Experimental Oncology, National Research Council, Via Pietro Castellino 111, Napoli, Italy  \nAbstract  \nADP-ribosyltransferases of the PARP family encompass a group of enzymes with variegated regulatory functions in cells, ranging from DNA damage repair to the control of cell-cycle progression and immune response. Over the years, this knowledge has led to the use of PARP1/2 inhibitors as mainstay pharmaceutical strategies for the treatment of ovarian, pancreatic, prostate and breast cancers, holding mutations in genes encoding for proteins involved in the DNA repair mechanisms (synthetic lethality) . Meanwhile, the last decade has witnessed significant progress in comprehending cellular pathways regulated by mono-ADP-ribosylation, with a huge effort in the development of novel selective compounds to inhibit those PARPs endowed with mono-ADP-ribosylation activity. This review focuses on the progress achieved in the cancer field, delving into most recent findings regarding the role of a subset of enzymes – the interferon-stimulated PARPs – in cancer progression.  \nIntroduction  \nADP-ribosylation is a reversible post-translational modification involved in several cellular processes, ranging from transcription, cell-cycle regulation and intracellular membrane transport to DNA-damage repair and stress-related responses (Ref. 1) . The reaction consists in the transfer of an ADP-ribose moiety from the donor nicotinamide adenine dinucleotide (NAD+) to acceptor proteins and/or nucleic acids (Refs 2, 3); this reaction is catalysed by ADP-ribosyltransferases (ARTs), while being reversed by glycosylhydrolases. By removing ADP-ribose units from the modified targets, these enzymes ensure the dynamic and reversible nature of ADP-ribosylation, allowing cells to rapidly respond to different physiological and environmental stimuli (Ref. 4) .  \nIntracellularly, ADP-ribosylation is mainly operated by enzymes of the PARP family, which consists of 17 members that, based on their catalytic activity, are grouped into mono-ARTs (PARP3, 4, 6–12, 14–16) or poly-ARTs (PARP1, PARP2 and PARP5a/5b); to date, only PARP13 is considered as an inactive enzyme (Ref. 1) . PARPs can transfer either single or multiple units of ADP-ribose, and we will refer to mono-ADP-ribosylation (MARylation) or poly-ADP-ribosylation (PARylation), respectively. The last two decades have been characterised by improvements in the tools to detect the modification, leading to a wider understanding of the roles played by the different enzymes. More in details, mono-ARTs appear to be involved in the regulation of signalling pathways altered in cancers and therefore can be considered as innovative targets for integrated therapeutic approaches. This review provides a ","cbCaiuDsT9ifWvwf","https://ap.wps.com/l/cbCaiuDsT9ifWvwf","pdf",381007,"English","# Abstract\n# Introduction\n# PARP7","[{\"question\":\"What is mono-ADP-ribosylation and how is it related to PARP enzymes?\",\"answer\":\"Mono-ADP-ribosylation refers to transfer of single ADP-ribose units to targets. PARP family enzymes mainly drive intracellular ADP-ribosylation, with PARPs categorized into mono-ARTs and poly-ARTs based on catalytic activity.\"},{\"question\":\"Why are PARP1/2 inhibitors important in cancer therapy?\",\"answer\":\"PARP1/2 inhibitors are used as mainstay pharmaceutical strategies for ovarian, pancreatic, prostate, and breast cancers. Their effectiveness is linked to mutations in genes involved in DNA repair mechanisms, described as synthetic lethality.\"},{\"question\":\"How does PARP7 influence interferon type I signaling in cancer cells?\",\"answer\":\"PARP7 acts as a repressor of the interferon type I (IFN-I) pathway by MARylating and deactivating pathway components, such as TBK1. This negative regulation helps cancer cells escape immune surveillance.\"}]","PARP enzymes and mono-ADP-ribosylation - advancing the connection from interferonsignalling to cancer biology | PDF",1790022667,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/563fded72ac76aeaa963cd6b163c15cf.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe0e2ae9ef80a070be4917f56967521e.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/076d61976cc71d405450a5a1ba3102e2.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e1522674f256f8b17f502b07a11ff68.webp",980,1385]